Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
BioPharma Dive5d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
GEN - Genetic Engineering and Biotechnology News20h
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
MedPage Today on MSN6d
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy
A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
BioSpace5d
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
WIVB-TV5d
Patient dies following muscular dystrophy gene therapy, Sarepta reports
WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%.
pharmaphorum6d
Sarepta bags key expansion to DMD gene therapy label in US
Sarepta’s gene therapy for Duchenne muscular ... In particular, it highlighted “compelling” improvements over placebo on secondary endpoints like improvements in time to rise from the ...
Hosted on MSN3mon
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
Sarepta Therapeutics has completed enrolment ... involves ambulatory and non-ambulatory subjects aged four and above. Secondary endpoints and outcomes will assess functional measures up to month ...